Nasdaq grts.

Today’s penny stock pick is the clinical-stage biotechnology company, Gritstone bio, Inc. (NASDAQ: GRTS). Gritstone bio, Inc. engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, a neoantigen-based immunotherapy, which is in Phase …EMERYVILLE, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today ...Simon is currently serving on the Board of Directors of Gritstone Oncology (NASDAQ: GRTS) and Sientra (NASDAQ:SIEN). Mr. Simon received a BS degree in ...Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.

EMERYVILLE, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today ...EMERYVILLE, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today ...Find the latest news headlines from Gritstone bio, Inc. Common Stock (GRTS) at Nasdaq.com.

GRTS Latest Real Time Trades. Select time range to see more trades: Last 100 Trades. NLS Time (ET) NLS Price. NLS Share Volume. 16:00:04. $ 2.64. 861.Web

Find the latest on option chains for Gritstone bio, Inc. Common Stock (GRTS) at Nasdaq.com.Gritstone bio, Inc. Common Stock (GRTS) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.WebDec 14, 2022 · Feb 10,2023 - GRTS STOCK PRICE DECREASE: Gritstone bio Inc on 02-10-2023 decreased stock price > 10% from $3.26 to $2.90. Dec 15,2022 - GRTS STOCK PRICE INCREASE: Gritstone bio Inc on 12-15-2022 increased stock price > 10% from $3.11 to $3.92. Dec 14,2022 - GRTS STOCK PRICE INCREASE: Gritstone bio Inc on 12-14-2022 increased stock price > 10% ... The largest stake in Gritstone Oncology, Inc. (NASDAQ:GRTS) was held by Redmile Group, which reported holding $26.8 million worth of stock at the end of September.It was followed by Casdin Capital ...

Gritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology company that aims to create the world’s most potent vaccines. We leverage our innovative vectors and payloads to train multiple arms of the immune system to attack critical disease targets. Independently and with our collaborators, we are advancing a portfolio of product ...

About Gritstone bio Gritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology company that aims to create the world’s most potent vaccines. We leverage our innovative vectors and ...

Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Gritstone ...Eric Enderson. November 21, 2023. In the last trading session, 1.28 million Gritstone Bio Inc (NASDAQ:GRTS) shares changed hands as the company’s beta touched 0.47. With the company’s per share price at $1.32 changed hands at -$0.04 or -2.94% during last session, the market valuation stood at $125.85M. GRTS’s last price was a discount ...Based on analysts offering 12 month price targets for GRTS in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .Gritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology company that aims to create the world’s most potent vaccines. We leverage our innovative vectors and payloads to train multiple arms of the immune system to attack critical disease targets. Independently and with our collaborators, we are advancing a portfolio of product ...Gritstone bio Inc (NASDAQ:GRTS) has shared data from the first cohort (10 µg dose) of the Phase 1 booster trial of self-amplifying mRNA (samRNA) COVID-19 vaccine.

Dec 1, 2023 · The following insider purchased GRTS shares in the last 24 months: Vassiliki Economides ($22,800.00). How much insider buying is happening at Gritstone bio? Insiders have purchased a total of 12,000 GRTS shares in the last 24 months for a total of $22,800.00 bought. Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, a neoantigen-based immunotherapy, which is in Phase 2/3 clinical trials for the treatment of solid tumors, including microsatellite stable ...Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.As published in their initiating research note from Evercore ISI on March 31, 2023, Gritstone Bio Inc [GRTS] has been an Outperform. Analyzing GRTS Stock Performance. On Wednesday, Gritstone Bio Inc [NASDAQ: GRTS] plunged -7.65% to $1.69. The stock’s lowest price that day was $1.66, but it reached a high of $1.82 in the …... bio Inc. GRTS (U.S.: Nasdaq). search. View All companies. AT CLOSE 4:00 PM EST 11/30/23. $1.30 USD; -0.02 -1.52%. Volume 1,713,603. AFTER HOURS 6:52 PM EST 11 ...Mar 8, 2022 · Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.

Find out why GRTS stock is a Hold. ... (NASDAQ:GRTS) in the spotlight. The company is advancing its pipeline on several fronts, has a collaboration deal with a well-known drug maker, and its lead ...

Today’s penny stock pick is the clinical-stage biotechnology company, Gritstone bio, Inc. (NASDAQ: GRTS). Gritstone bio, Inc. engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, a neoantigen-based immunotherapy, which is in Phase …EMERYVILLE, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced... -- 10,000 participant randomized Phase 2b study will evaluate Gritstone s self-amplifying mRNA (samRNA) vaccine candidate containing Spike plus ... As of August 31, 2023, the average one-year price target for Gritstone Bio is 8.77. The forecasts range from a low of 2.02 to a high of $21.00. The average price target represents an increase of ...Gritstone Bio Inc (NASDAQ:GRTS)’s traded shares stood at 0.86 million during the last session, with the company’s beta value hitting 0.59. At the close of trading, the stock’s price was $1.88, to imply an increase of 2.73% or $0.05 in intraday trading. The GRTS share’s 52-week high remains $4.05, putting it -115.43% down since that peak ...Oct 30, 2023 · In the last trading session, 1.12 million Gritstone Bio Inc (NASDAQ:GRTS) shares changed hands as the company’s beta touched 0.61. With the company’s per share price at $1.89 changed hands at -$0.06 or -3.08% during last session, the market valuation stood at $175.92M. GRTS’s last price was a The largest stake in Gritstone Oncology, Inc. (NASDAQ:GRTS) was held by Redmile Group, which reported holding $26.8 million worth of stock at the end of September.It was followed by Casdin Capital ...Gritstone bio, Inc. (NASDAQ:GRTS – Free Report) – Research analysts at HC Wainwright upped their FY2023 EPS estimates for Gritstone bio in a research report issued on Thursday, November 9th.

EMERYVILLE, Calif., April 10, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today ...

Eric Enderson. November 21, 2023. In the last trading session, 1.28 million Gritstone Bio Inc (NASDAQ:GRTS) shares changed hands as the company’s beta touched 0.47. With the company’s per share price at $1.32 changed hands at -$0.04 or -2.94% during last session, the market valuation stood at $125.85M. GRTS’s last price was a discount ...

EMERYVILLE, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today ...Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.Jan 13, 2022 · Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Based on analysts offering 12 month price targets for GRTS in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .Nov 21, 2023 · Eric Enderson. November 21, 2023. In the last trading session, 1.28 million Gritstone Bio Inc (NASDAQ:GRTS) shares changed hands as the company’s beta touched 0.47. With the company’s per share price at $1.32 changed hands at -$0.04 or -2.94% during last session, the market valuation stood at $125.85M. GRTS’s last price was a discount ... EMERYVILLE, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today ...Gritstone bio, Inc. (GRTS) NasdaqGS - NasdaqGS Real Time Price. Currency in USD. Follow. 2W 10W 9M. 1.3700 +0.0500 (+3.79%) At close: 01:00PM EST. 1.3700 0.00 …WebBased on analysts offering 12 month price targets for GRTS in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .Nov 24, 2023 · Gritstone bio (GRTS) Stock Price, News & Analysis $1.37 -0.01 (-0.72%) (As of 11/14/2023 ET) Compare Today's Range $1.36 $1.49 50-Day Range $1.19 $2.85 52-Week Range $1.14 $4.05 Volume 1.57 million shs Average Volume 1.17 million shs Market Capitalization $130.62 million P/E Ratio N/A Dividend Yield N/A Price Target $7.33 Sep 16, 2021 · Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Gritstone ... Nov 10, 2023 · During the recent session, Gritstone Bio Inc (NASDAQ:GRTS)’s traded shares were 0.46 million, with the beta value of the company hitting 0.56. At the last check today, the stock’s price was $1.46, reflecting an intraday loss of -6.73% or -$0.1. The 52-week high for the GRTS share is $4.05, that ...

Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.Find the latest Institutional Holdings data for Gritstone bio, Inc. Common Stock (GRTS) at Nasdaq.com.EMERYVILLE, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, announced ...Instagram:https://instagram. beacon roofing supply stockpgande stockscharles schwab stock dividendbest mortgage lenders in nevada During the recent session, Gritstone Bio Inc (NASDAQ:GRTS)’s traded shares were 0.46 million, with the beta value of the company hitting 0.56. At the last check today, the stock’s price was $1.46, reflecting an intraday loss of -6.73% or -$0.1. The 52-week high for the GRTS share is $4.05, that puts it down -177.4 from that peak though ...Celebrations may be in order for Gritstone bio, Inc. (NASDAQ:GRTS) shareholders, with the analysts delivering a significant upgrade to their statutory estimates for the company. The analysts have ... stock market demomarkets next week Verizon, Walgreens, and 4 Other Stocks. The S&P 500's Best Payouts: 7%+ Dividend Yields. Get the latest GRTS (GRTS) real-time quote, historical performance, charts, and other financial...Management criteria checks 3/4. Gritstone bio's CEO is Andrew Allen, appointed in Aug 2015, has a tenure of 8.25 years. total yearly compensation is $2.68M, comprised of 23.2% salary and 76.8% bonuses, including company stock and options. directly owns 1.6% of the company’s shares, worth $2.07M. The average tenure of the management team and ... best books on futures trading Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of cancer immunotherapies to fight multiple cancer types. Gritstone develops its ...Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.